有救了！I型糖尿病II期临床试验新进展，首位病人已进组！

张通社获悉，7月9日，上海研健新药研发有限公司（以下简称“研健医药”）宣布YG1699 I型糖尿病II期临床试验在美国开展，第一位病人已在今天入组并接受YG1699 治疗。在这之后将接连会有更多病人开始入组加入实验。本次I型糖尿病IIa实验预计年底结束。

ZhangTongShe, June 9 - Youngene Therapeutics Announced Today：The first patient has been enrolled in and received the treatment of YG1699. In the next a few days, successive patients will start to join the trial. The Type 1 Diabetes IIa trial is expected to finish by the end of this year.

研健新药是一家拥有临床II期产品、专注于代谢疾病的新药研发公司，目前已经建立了多条研发管线。先导产品YG1699的临床I期在美国已经完成，I型糖尿病的II期临床正在美国进行，目前病人已入组；中国的临床桥接实验也已经开始；另外有多个产品处于临床前开发阶段。

Youngene Therapeutics Co. Ltd, a Clinical - Phase II stage pharmaceutical company. Founded in 2016 in China. We have established an innovative and differentiated pipeline of several programs mainly focusing on metabolic disease. YG1699, one of the leading product has completed Phase I study in USA. The Phase II study has been initiated in the United States. Chinese clinical bridging study has also initiated in China.

编辑：黄蓉蓉

来源：企业供稿